Yang WT - Search Results

1

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.

Dai LJ, Ma D, Xu YZ, Li M, Li YW, Xiao Y, Jin X, Wu SY, Zhao YX, Wang H, Yang WT, Jiang YZ, Shao ZM. Dai LJ, et al. Among authors: yang wt. Nat Commun. 2023 Aug 22;14(1):5112. doi: 10.1038/s41467-023-40715-x. Nat Commun. 2023. PMID: 37607916 Free PMC article.

2

Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.

Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X, Zhou X. Zhu X, et al. Hum Pathol. 2011 Oct;42(10):1499-504. doi: 10.1016/j.humpath.2010.04.023. Epub 2011 Jun 14. Hum Pathol. 2011. PMID: 21676436

3

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.

Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, Geng C, Shao Z. Huang L, et al. Oncotarget. 2015 Jul 30;6(21):18683-92. doi: 10.18632/oncotarget.4337. Oncotarget. 2015. PMID: 26084292 Free PMC article. Clinical Trial.

4

HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.

Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y, Yang W. Li A, et al. Oncotarget. 2016 Jun 21;7(25):37966-37978. doi: 10.18632/oncotarget.9274. Oncotarget. 2016. PMID: 27177225 Free PMC article.

5

Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.

Xu Y, Bi R, Xiao Y, Tu X, Li M, Li A, Shan L, Zhou S, Yang W. Xu Y, et al. Diagn Pathol. 2017 Dec 22;12(1):87. doi: 10.1186/s13000-017-0679-3. Diagn Pathol. 2017. PMID: 29273082 Free PMC article.

6

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.

Li M, Li A, Zhou S, Xu Y, Xiao Y, Bi R, Yang W. Li M, et al. BMC Cancer. 2018 Jan 2;18(1):4. doi: 10.1186/s12885-017-3916-y. BMC Cancer. 2018. PMID: 29291717 Free PMC article.

7

Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer.

Zhou S, Sun X, Yu L, Zhou R, Li A, Li M, Yang W. Zhou S, et al. J Cancer. 2018 Jan 5;9(3):604-613. doi: 10.7150/jca.19190. eCollection 2018. J Cancer. 2018. PMID: 29483966 Free PMC article.

8

SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.

Li M, Li A, Zhou S, Lv H, Yang W. Li M, et al. J Hematol Oncol. 2019 Feb 8;12(1):14. doi: 10.1186/s13045-019-0700-2. J Hematol Oncol. 2019. PMID: 30736840 Free PMC article.

9

Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.

Shui R, Liang X, Li X, Liu Y, Li H, Xu E, Zhang Z, Lian Y, Guo S, Yao M, Yang H, Xu F, Liu Y, Liu J, Guo D, Wang K, Li J, Ma Y, Wang J, Shi J, Bu H, Yang W. Shui R, et al. Clin Breast Cancer. 2020 Feb;20(1):e65-e74. doi: 10.1016/j.clbc.2019.07.013. Epub 2019 Aug 23. Clin Breast Cancer. 2020. PMID: 31669267

10

Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma.

Zhou S, Yang F, Bai Q, Li A, Li M, Zhong S, Lv H, Shui R, Tu X, Bi R, Xu X, Cheng Y, Yu B, Tang S, Sun X, Zhou X, Yang W. Zhou S, et al. Mod Pathol. 2020 Jul;33(7):1275-1286. doi: 10.1038/s41379-020-0461-z. Epub 2020 Jan 23. Mod Pathol. 2020. PMID: 31974492 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

649 results

Search Page